Mednax, Inc. (MD): Price and Financial Metrics
Mednax, Inc. (MD)
Today's Latest Price: $23.60 USD
Updated Jan 15 7:00pm
Add MD to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 77 in Medical - Services
See all "A" rated Strong Buy stocks
MD Stock Summary
- Mednax Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 85.55% of US listed stocks.
- Revenue growth over the past 12 months for Mednax Inc comes in at -23.15%, a number that bests just 15.57% of the US stocks we're tracking.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for MD comes in at 10.35% -- higher than that of 83.78% of stocks in our set.
- Stocks that are quantitatively similar to MD, based on their financial statements, market capitalization, and price volatility, are BBCP, HMTV, TTMI, PACK, and SUM.
- Visit MD's SEC page to see the company's official filings. To visit the company's web site, go to www.mednax.com.
MD Stock Price Chart Interactive Chart >
MD Price/Volume Stats
| Current price | $23.60 | 52-week high | $27.86 |
| Prev. close | $23.91 | 52-week low | $7.37 |
| Day low | $23.44 | Volume | 419,400 |
| Day high | $24.05 | Avg. volume | 1,027,890 |
| 50-day MA | $21.58 | Dividend yield | N/A |
| 200-day MA | $17.75 | Market Cap | 2.02B |
Mednax, Inc. (MD) Company Bio
MEDNAX Inc. provides neonatal, anesthesia, maternal-fetal, and other pediatric subspecialties physician services in the United States and Puerto Rico. The company was founded in 1979 and is based in Sunrise, Florida.
MD Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $23.60 | $10.51 | -55% |
We started the process of determining a valid price forecast for Mednax Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Mednax Inc ranked in the 33th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 55.17%. The most interesting components of our discounted cash flow analysis for Mednax Inc ended up being:
- Interest coverage, a measure of earnings relative to interest payments, is -5.34 -- which is good for besting only 12.87% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
- Its compound free cash flow growth rate, as measured over the past 5.53 years, is -0.04% -- higher than merely 19.21% of stocks in our DCF forecasting set.
- Mednax Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -56% |
| 1% | -56% |
| 2% | -55% |
| 3% | -55% |
| 4% | -55% |
| 5% | -54% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as MD, try GILD, A, BIO, RGEN, and BAX.
Loading social stream, please wait...